UK & World

Rare thrombotic cases decrease after younger than 40 years provide alternative jabs

There is no new case Rare blood clots associated with the Oxford / AstraZeneca Covid-19 vaccine Seen by scientists last month following the decision to offer an alternative jab under the age of 40.

A group of British scientists said Joint Committee Decision on Immunization and Immunization (JCVI) was undoubtedly effective in reducing reports of the very rare adverse event of thrombotic and platelet count reduction after the first dose of the Oxford / AstraZeneca vaccine.

They have now set up guidance for clinicians to help identify markers associated with blood clots and diagnose what is called vaccine-induced immune thrombocytopenia and thrombosis (Vitt). This can treat the condition more effectively and increase the chances of survival.

According to their findings, New England Journal of MedicineScientists said the overall mortality rate for people who came to the hospital with a clear or possible wit was 23 percent.

They said that if the patient’s platelet count was very low, the chances of death would increase. However, treatments such as plasmapheresis, which involves removing a straw-colored liquid called plasma from the blood and replacing it with new plasma fluid, can dramatically increase the survival potential of people with severe illness. Experts said it could.

Dr Pavord, a consultant hematologist at the NHS Foundation Trust at Oxford University Hospital, said: It is especially dangerous if the patient has a low platelet count and has bleeding in the brain.

“Vit is a very new syndrome and we are still looking for the most effective treatment, but identifying prognostic markers determines more effective ways to manage the condition. It was useful. “

By July 28, this year, the Medicines and Healthcare Products Regulatory Agency had received reports of 411 major blood clots with simultaneous platelet count reductions in the United Kingdom after AstraZeneca vaccination.

According to MHRA, the overall case fatality rate was 18%, with 73 deaths, 6 of which occurred after the second dose. At that time, the estimated first dose of Oxford / AstraZeneca was 24.8 million and the estimated second dose was 23.6 million.

Dr. Pavold said: “It is important to emphasize that this type of response to the Oxford / AstraZeneca vaccine is extremely rare. The incidence of people under the age of 50 is about 1 in 50,000 vaccinated.”

She also said the team had never seen a new case of Vit in the last three to four weeks, suggesting that the decision to provide an alternative vaccine under the age of 40 may have played a role. increase.

Dr. Pavod said: “I haven’t seen any new cases in the last four weeks, which is very reassuring.”

Rare thrombotic cases decrease after younger than 40 years provide alternative jabs

Source link Rare thrombotic cases decrease after younger than 40 years provide alternative jabs

Related Articles

Back to top button